CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note released on Tuesday,Benzinga reports. They currently have a $65.00 price target on the stock.

A number of other brokerages have also commented on CRSP. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, May 16th. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Stifel Nicolaus reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $71.75.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $39.25 on Tuesday. The company’s 50 day moving average price is $37.34 and its two-hundred day moving average price is $42.22. The firm has a market capitalization of $3.39 billion, a P/E ratio of -8.98 and a beta of 1.88. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The firm’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same period last year, the business earned ($1.43) EPS. On average, analysts expect that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, Director John Greene bought 7,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,021 shares of company stock valued at $594,771 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Intellectus Partners LLC increased its holdings in shares of CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock worth $281,000 after purchasing an additional 250 shares during the period. Farrow Financial Inc. increased its stake in CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after acquiring an additional 270 shares during the last quarter. Kestra Private Wealth Services LLC increased its stake in CRISPR Therapeutics by 1.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock worth $812,000 after acquiring an additional 310 shares during the last quarter. SFE Investment Counsel raised its holdings in shares of CRISPR Therapeutics by 5.8% in the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock valued at $221,000 after acquiring an additional 355 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in CRISPR Therapeutics by 7.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after purchasing an additional 372 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.